Bioscan is a leading developer of advanced instrumentation for the detection, synthesis, and imaging of Radio labeled Compounds used in four areas:
- Life Science Research
- Molecular Imaging
- Pharmaceutical Development
- Nuclear Medicine
Founded in 1980, Bioscan has supplied customers with unique research productivity tools for more than 25 years.
Thousands of customers worldwide--in universities, research hospitals, government laboratories, and pharmaceutical companies--use Bioscan products for basic biomedical research and for the production of radiopharmaceuticals.
With the introduction of its NanoSPECT/CT in vivo imaging system in 2006 and the NanoPET/CT in 2010, Bioscan set a new standard in the field of molecular imaging of animal models for biological & disease research.
Bioscan facilitates early disease diagnosis--and accelerates drug discovery--by providing innovative technologies for bio-tracer chemistry and preclinical imaging. Our goal is to provide researchers with reliable, flexible, and easy-to-use instrumentation that offers state-of-the-art performance capabilities.
Bioscan, Inc. Activity on LinkedIn
-
-
-
Bioscan, Inc. Bioscan opens molecular R&D center in France Bioscan is opening a new research facility, Bioscan Molecular Imaging France (BMIF), in Dijon, France, which is enjoying a growing reputation for academic research in molecular imaging. In March 2011, the Washington, DC-based company was one of eight companies awarded a 7.3 million euro grant to develop a combined PET/MRI system for in vivo animal imaging. Bioscan will serve as the lead for the project, known as Integrated Magnetic Resonance and Positron Emission Tomography in Preclinical Imaging (IMAPPI). Read more: http://www.bioscan.com/bmif
